Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Sortiert nach
    Datensatz exportieren als...
  • BibTeX
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial
Journal of clinical oncology, 2018-07, Vol.36 (20), p.2024-2034
2018
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
Therapeutic advances in medical oncology, 2021, Vol.13, p.17588359211012361-17588359211012361
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Radiation and Dose‐densification of R‐CHOP in Aggressive B‐cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
HemaSphere, 2023-07, Vol.7 (7), p.e904-n/a
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
S200: IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF THE PHASE 3, DOUBLE‐BLIND, PLACEBO‐CONTROLLED CLL12 TRIAL
HemaSphere, 2023-08, Vol.7 (S3), p.e9488123-n/a
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
P630: SAFETY AND TREATMENT ADHERENCE WITH ACALABRUTINIB IN VERY OLD (≥80Y) AND/OR FRAIL PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ‐ INTERIM SAFETY ANALYSIS OF THE ONGOING PHASE‐II CLL‐FRAIL TRIAL
HemaSphere, 2023-08, Vol.7 (S3), p.e3844763-n/a
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer
The New England journal of medicine, 2019-02, Vol.380 (8), p.720-728
2019
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia
The New England journal of medicine, 2023-05, Vol.388 (19), p.1739-1754
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia
Blood, 2022-01, Vol.139 (2), p.177-187
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial
Nature medicine, 2024-01, Vol.30 (1), p.240-248
2024
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
The lancet oncology, 2018-11, Vol.19 (11), p.1530-1542
2018
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
FOOTPATH: A randomized, open-label phase-2 study of liposomal irinotecan + 5-FU and folinic acid (NAPOLI) versus sequential NAPOLI and mFOLFOX6 versus gemcitabine/nab-paclitaxel in treatment-naïve metastatic pancreatic cancer (mPDAC)
Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4021-4021
2023
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Efficacy of afatinib in the clinical practice: Final results of the GIDEON study in EGFR mutated non-small cell lung cancer (NSCLC) in Germany
Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e21636-e21636
2020
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
The Lancet. Haematology, 2022-11, Vol.9 (11), p.e810-e821
2022
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations
Blood, 2023-08, Vol.142 (5), p.446-459
2023
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Fludarabine, Cyclophosphamide and Rituximab (FCR) As First Line Treatment in Patients with Chronic Lymphocytic Leukemia (CLL): A Long-Term Analysis of the German CLL Study Group (GCLLSG) Registry
Blood, 2022-11, Vol.140 (Supplement 1), p.9879-9881
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry
The European respiratory journal, 2023-02, Vol.61 (2), p.2201336
2023
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma: A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis
Blood, 2021-11, Vol.138 (Supplement 1), p.4533-4533
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Outcomes of anti‐programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real‐world analysis
British journal of haematology, 2022-07, Vol.198 (2), p.401-404
2022
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Fludarabine, cyclophosphamide, and rituximab as first‐line treatment in patients with chronic lymphocytic leukemia: A long‐term analysis of the German CLL Study Group (GCLLSG) registry
European journal of haematology, 2024-08, Vol.113 (2), p.235-241
2024
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
A Randomized Phase III Study of Venetoclax-Based Time-Limited Combination Treatments (RVe, GVe, GIVe) Vs Standard Chemoimmunotherapy (CIT: FCR/BR) in Frontline Chronic Lymphocytic Leukemia (CLL) of Fit Patients: First Co-Primary Endpoint Analysis of the International Intergroup GAIA (CLL13) Trial
Blood, 2021-11, Vol.138 (Supplement 1), p.71-71
2021
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study
Leukemia, 2018-12, Vol.32 (12), p.2558-2571
2018
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)
Blood, 2017-12, Vol.130, p.483-483
2017
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trial
Annals of hematology, 2019-04, Vol.98 (4), p.897-907
2019
Volltextzugriff (PDF)
    Datensatz exportieren als...
  • BibTeX
Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial)
Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7515-7515
2018
Volltextzugriff (PDF)
Open Access
    Datensatz exportieren als...
  • BibTeX
Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia
Blood, 2010-11, Vol.116 (18), p.3564-3571
2010
Volltextzugriff (PDF)
1 – 25 von 40
Suche als RSS-Feed
Suchergebnisse filtern
Filter anzeigen